Genmab is an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

shutterstock_124071745_resized for site2016 Full Year Financial Results

Genmab will report its 2016 Full Year financial results after market close on February 22. An investor conference call to discuss the results will be held at 6PM CET / 12PM EST on February 22. To join the call by phone, dial one of the following numbers and ask for the Genmab conference call: +45 3271 1660 in Denmark, +44 20 3427 1912 in the UK or +1 646 254 3363 in the US. Click here to listen to the webcast. 


InvestorPortal

To register your email address for electronic shareholder communications or to update your settings, log on to the InvestorPortal


 

5 Dec 150x110ASH 2016 Data Review Meeting

Genmab hosted an ASH 2016 Data Review Meeting on December 5 in San Diego, CA.The meeting included the presentation of daratumumab data presented at the 2016 American Society of Hematology Annual Meeting (December 3-6).The event was also be webcast and an archive of the webcast is available here.  To download the slides of the presentation, click hereThis meeting was NOT an official program of the ASH Annual Meeting.